Receptors, Urokinase Plasminogen Activator
"Receptors, Urokinase Plasminogen Activator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An extracellular receptor specific for UROKINASE-TYPE PLASMINOGEN ACTIVATOR. It is attached to the cell membrane via a GLYCOSYLPHOSPHATIDYLINOSITOL LINKAGE and plays a role in the co-localization of urokinase-type plasminogen activator with PLASMINOGEN.
| Descriptor ID |
D055293
|
| MeSH Number(s) |
D12.776.395.550.448.813 D12.776.543.484.500.813 D12.776.543.550.418.813 D12.776.543.750.815
|
| Concept/Terms |
Receptors, Urokinase Plasminogen Activator- Receptors, Urokinase Plasminogen Activator
- CD87 Antigen
- Antigen, CD87
- Plasminogen Activator Receptor, Urokinase Type
- Plasminogen Activator, Urokinase Receptor
- Urokinase-Type Plasminogen Activator Receptors
- Urokinase Type Plasminogen Activator Receptors
- Receptor, Pro-Urokinase
- Pro-Urokinase Receptor
- Receptor, Pro Urokinase
- Receptor, Urokinase Plasminogen Activator
- U-PA Receptor
- Receptor, U-PA
- U PA Receptor
- Upar Receptor
- Receptor, Upar
- Urokinase Plasminogen Activator Receptors
- Antigens, CD87
- CD87 Antigens
- Plasminogen Activator, Urokinase Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Urokinase Plasminogen Activator".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Urokinase Plasminogen Activator".
This graph shows the total number of publications written about "Receptors, Urokinase Plasminogen Activator" by people in this website by year, and whether "Receptors, Urokinase Plasminogen Activator" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2017 | 16 | 3 | 19 |
| 2018 | 10 | 0 | 10 |
| 2019 | 6 | 0 | 6 |
| 2020 | 2 | 0 | 2 |
| 2021 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Urokinase Plasminogen Activator" by people in Profiles.
-
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021 10; 27(10):1752-1760.
-
Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients. Clin Chem Lab Med. 2021 10 26; 59(11):e413-e415.
-
Evaluation of the relationship between KIM-1 and suPAR levels and clinical severity in COVID-19 patients: A different perspective on suPAR. J Med Virol. 2021 Sep; 93(9):5568-5573.
-
Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study. Emerg Med J. 2021 Jul; 38(7):543-548.
-
Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study. Int J Infect Dis. 2021 Jun; 107:188-194.
-
Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department. J Emerg Med. 2021 09; 61(3):298-313.
-
An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife. 2021 03 08; 10.
-
Plasma levels of the active form of suPAR are associated with COVID-19 severity. Crit Care. 2020 12 29; 24(1):704.
-
Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients. Mol Diagn Ther. 2020 10; 24(5):517-521.
-
Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. J Am Soc Nephrol. 2020 11; 31(11):2725-2735.